Program
Tirzepatide
Also written as “Arm 5- Tirzepatide”, “Tirzepatide Dose 1” and “Tirzepatide Dose 2”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus, Type 1 · Psoriasis · Non-alcoholic Fatty Liver Disease, led by 4 companies.
Drug pageTirzepatide: every studyAll 192 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 6917 open or running | phase 4since Jun 22, 2022 | Apr 29, 2016 | Nov 2026phase 1 · NCT07299084 |
| Florida Academic Centers Research and Educationits history only | 11 open or running | no phasesince Mar 1, 2024 | Mar 1, 2024 | none ahead |
| Hudson Biotechits history only | 11 open or running | phase 3since Mar 8, 2026 | Mar 8, 2026 | Feb 14, 2027phase 3 · NCT07481747 |
| Lexaria Bioscienceits history only | 10 open or running | phase 1since Oct 16, 2024 | Oct 16, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 42 earlier studies, Mar 19, 2019 to Oct 4, 2023.
- Jun 9, 2018Named tirzepatideINNProposed as its International Nonproprietary Name in WHO's List 119
- May 28, 2024Phase 3 study in ObesityNCT06439277 · 300 planned · United States, Argentina, Australia and more
- Sep 4, 20242 phase 3 studiesNCT06588296, NCT06588283
- Oct 4, 2024Phase 4 study in Diabetes Mellitus, Type 2NCT06635057 · 166 enrolled · Saudi Arabia, United Arab Emirates
- Oct 14, 2024Phase 2 study in ObesityNCT06643728 · 252 enrolled · United States
- Mar 3, 20252 phase 4 studiesNCT06864026, NCT06857942
- Mar 24, 2025Phase 2 study in ObesityNCT06901349 · United States, Argentina, Canada and more
- Apr 4, 20253 phase 3 studiesNCT06914895, NCT06937099, NCT06937086
- May 6, 2025Phase 3 study in Diabetes Mellitus, Type 1NCT06962280 · 465 enrolled · United States, Argentina, Brazil and more
- Aug 28, 2025Phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT07165028 · 4,500 planned · United States, Argentina, Australia and more
- Nov 19, 2025Phase 4 study in ObesityNCT07247084 · 3,000 planned · United Kingdom
- Dec 10, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07299084 · 40 enrolled · Singapore
- Feb 23, 2026Phase 4 study in Diabetes Mellitus, Type 2NCT07438444 · 344 enrolled · India
- Sep 1, 2026Phase 1 study in Diabetes Mellitus, Type 1NCT07803744 · 18 planned · United States
- Sep 9, 2026Phase 3 study in ObesityNCT07817875 · 150 planned · United States, Belgium, Israel and more
Ahead
- Nov 2026Primary completion: phase 1 study in Diabetes Mellitus, Type 2NCT07299084
- Nov 2026Primary completion: phase 3 study in Diabetes Mellitus, Type 1NCT06962280
- Nov 2026Primary completion: phase 3 study in Diabetes Mellitus, Type 1NCT06914895
- Dec 2026Primary completion: phase 1 study in Diabetes Mellitus, Type 1NCT07803744
TargetBeta
“Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| brenipatide | Eli Lilly | phase 3 | 19 |
| olatorepatide | Hansoh Pharmaceutical Group | phase 3 | 12 |
| UBT251 | The United Laboratories International | phase 3 | 12 |
| enicepatide | Hoffmann-La Roche | phase 3 | 10 |
| VK2735rule | Viking Therapeutics | phase 3 | 8 |
| NNC0519-0130 | Novo Nordisk | phase 2 | 11 |
| BI 3034701 | Boehringer Ingelheim | phase 2 | 6 |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 5 |
| NA-931rule | biomed-industries-inc | phase 2 | 3 |
Studies
The newest 60 of 69 Eli Lilly leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07817875Obesity · United States, Belgium, Israel and more | 3 | Recruiting | Dec 2029 | 150 |
| NCT07803744Diabetes Mellitus, Type 1 · United States | 1 | Recruiting | Dec 2026 | 18 |
| NCT07438444Diabetes Mellitus, Type 2 · India | 4 | Active, not recruiting | Jul 2027 | 344 |
| NCT07299084Diabetes Mellitus, Type 2 · Singapore | 1 | Active, not recruiting | Nov 2026 | 40 |
| NCT07247084Obesity · United Kingdom | 4 | Recruiting | Jul 2029 | 3,000 |
| NCT07165028Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more | 3 | Recruiting | Aug 2030 | 4,500 |
| NCT06962280Diabetes Mellitus, Type 1 · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Nov 2026 | 465 |
| NCT06937099Crohn Disease · United States, Austria, Belgium and more | 3 | Recruiting | May 2028 | 290 |
| NCT06937086Colitis, Ulcerative · United States, Austria, Belgium and more | 3 | Recruiting | Apr 2028 | 350 |
| NCT06914895Diabetes Mellitus, Type 1 · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Nov 2026 | 905 |
| NCT06901349Obesity · United States, Argentina, Canada and more | 2 | Withdrawn | Jun 10, 2025 | 0 |
| NCT06864026Arthritis, Psoriatic · United States, Puerto Rico | 4 | Active, not recruiting | Aug 2027 | 200 |
| NCT06857942Psoriasis · United States | 4 | Recruiting | May 2028 | 200 |
| NCT06643728Obesity · United States | 2 | Completed | Jan 16, 2026 | 252 |
| NCT06635057Diabetes Mellitus, Type 2 · Saudi Arabia, United Arab Emirates | 4 | Completed | Apr 15, 2026 | 166 |
| NCT06588296Arthritis, Psoriatic · United States, Puerto Rico | 3 | Completed | Nov 18, 2025 | 279 |
| NCT06588283Psoriasis · United States, Puerto Rico | 3 | Completed | Jan 8, 2026 | 281 |
| NCT06439277Obesity · United States, Argentina, Australia and more | 3 | Recruiting | Oct 2027 | 300 |
| NCT06075667Obesity · United States, Canada, Czechia and more | 3 | Active, not recruiting | Jun 2, 2026 | 160 |
| NCT06047548Overweight · United States | 3 | Completed | Jan 20, 2026 | 441 |
| NCT06037252Diabetes Mellitus, Type 2 · United States, Argentina, Mexico and more | 2 | Active, not recruiting | Jan 8, 2026 | 414 |
| NCT05978713Healthy · United States | 1 | Completed | Mar 12, 2024 | 11 |
| NCT05963022Diabetes Mellitus, Type 2 · China | 3 | Completed | Oct 9, 2024 | 206 |
| NCT05810597Healthy · United States | 1 | Completed | Jul 17, 2023 | 65 |
| NCT05706506Diabetes Mellitus, Type 2 · United States | 4 | Completed | Oct 31, 2023 | 152 |
| NCT05696847Obesity · United States | 1 | Completed | Jan 16, 2025 | 28 |
| NCT05691712Diabetes Mellitus, Type 2 · China | 3 | Completed | Jul 1, 2024 | 257 |
| NCT05564039Diabetes Mellitus, Type 2 · United States, Belgium, Germany and more | 4 | Completed | Jul 15, 2024 | 282 |
| NCT05556512Obesity · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 2027 | 15,374 |
| NCT05822830Obesity · United States, Puerto Rico | 3 | Completed | Nov 13, 2024 | 751 |
| NCT05536804Overweight · United States, Austria, Canada and more | 2 | Completed | Jul 6, 2026 | 134 |
| NCT05433584Diabetes Mellitus, Type 2 · United States, Argentina, Canada and more | 4 | Active, not recruiting | Oct 21, 2025 | 794 |
| NCT05412004Sleep Apnea, Obstructive · United States, Australia, Brazil and more | 3 | Completed | Mar 12, 2024 | 469 |
| NCT05260021Diabetes Mellitus · United States, Australia, Brazil and more | 3 | Completed | Jul 30, 2024 | 99 |
| NCT05024032Obesity · China | 3 | Completed | Dec 27, 2022 | 210 |
| NCT04844918Obesity · Japan | 3 | Completed | Jun 24, 2023 | 267 |
| NCT04847557Obesity · United States, Argentina, Brazil and more | 3 | Completed | Jul 2, 2024 | 731 |
| NCT04660643Obesity · United States, Argentina, Brazil and more | 3 | Completed | Apr 25, 2023 | 783 |
| NCT04657016Obesity · United States, Argentina, Brazil and more | 3 | Completed | Apr 20, 2023 | 579 |
| NCT04657003Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Completed | Mar 16, 2023 | 938 |
| NCT04537923Diabetes Mellitus, Type 2 · United States, Argentina, Belgium and more | 3 | Completed | Oct 11, 2022 | 1,428 |
| NCT04407234Overweight · United States | 1 | Completed | Jan 7, 2021 | 36 |
| NCT04311424Healthy · United Kingdom | 1 | Completed | Oct 2, 2020 | 6 |
| NCT04311411Obesity · United States | 1 | Completed | Dec 16, 2022 | 114 |
| NCT04255433Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Jun 12, 2025 | 13,299 |
| NCT04235959Diabetes Mellitus, Type 2 · China | 1 | Completed | Aug 17, 2021 | 24 |
| NCT04184622Overweight · United States, Argentina, Brazil and more | 3 | Completed | Apr 1, 2022 | 2,539 |
| NCT04172987Healthy · United States | 1 | Completed | Feb 9, 2021 | 40 |
| NCT04166773Non-alcoholic Fatty Liver Disease · United States, Belgium, France and more | 2 | Completed | Dec 11, 2023 | 190 |
| NCT04093752Diabetes Mellitus, Type 2 · Australia, China, India and more | 3 | Completed | Nov 1, 2021 | 917 |
| NCT04081337Obesity · United States | 1 | Completed | May 26, 2022 | 55 |
| NCT04050670Healthy · United States | 1 | Completed | Apr 3, 2020 | 54 |
| NCT04050553Diabetes Mellitus, Type 2 · Austria | 1 | Completed | Jan 25, 2022 | 42 |
| NCT04039503Diabetes Mellitus, Type 2 · United States, Czechia, Germany and more | 3 | Completed | Dec 22, 2020 | 475 |
| NCT04004988Healthy · Singapore | 1 | Completed | Dec 16, 2019 | 47 |
| NCT03987919Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Jan 28, 2021 | 1,879 |
| NCT03954834Diabetes Mellitus, Type 2 · United States, India, Japan and more | 3 | Completed | Oct 5, 2020 | 478 |
| NCT03951753Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Apr 8, 2021 | 117 |
| NCT03940742Hepatic Insufficiency · United States | 1 | Completed | Sep 22, 2020 | 32 |
| NCT03882970Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more | 3 | Completed | Dec 11, 2020 | 1,444 |
How it is read
Names in the registry
- “Tirzepatide”, 69 entries
- “Arm 5- Tirzepatide”, 1 entry
- “Tirzepatide Dose 1”, 1 entry
- “Tirzepatide Dose 2”, 1 entry
- “TIRZEPATIDE”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 29 studies
- Obesity, 21 studies
- Diabetes Mellitus, Type 1, 3 studies
- Psoriasis, 2 studies
- Non-alcoholic Fatty Liver Disease, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.